Cosentyx has a strong launch in the AS market, with increasing availability of safety and efficacy data expected to drive its use.
By Manoli Kavishwar, Analyst
13 September 2016
I am an analyst at Datamonitor Healthcare, based in the London office, where I am a member of the Immunology and Inflamm...
Read full bio
Despite long term physician and patient familiarity with anti-tumor necrosis factor (TNF) inhibitors, Cosentyx (secukinumab; Novartis) has shown positive uptake during its first year in the axial spondyloarthritis (axSpA) market, with a favorable safety and efficacy profile and increasing availability of further long-term clinical data expected to drive its use. Cosentyx is currently prescribed for patients following the failure of at least one anti-TNF biologic. The strong launch trajectory has been reflected in Novartis’ Q2 2016 financial report, with Cosentyx reported to have achieved global sales of $260m. Discussions with key opinion leaders have revealed that, based on its clinical performance in axSpA so far, Cosentyx’s clinical and safety profile is considered to be on par with that of anti-TNF inhibitors.
“The data seen from the phase III clinical trial was indeed very good; actually it (Cosentyx) showed a better profile than the first phase III trial data with TNF inhibitors…so that looks at least very good.” Key opinion leader
However, key opinion leaders note that further data is required to answer concerns about a potential correlation with inflammatory bowel disease (IBD), as well as to ensure Cosentyx can maintain its favorable clinical performance in the long term.
“I do have some concerns…with regards to inflammatory bowel disease, because when studied in IBD people flared…and I do worry that if you block IL-17 in someone with even subclinical gut inflammation you may unmask IBD…so I think we need longer term studies to really know beyond the clinical response what the outcomes are going to be.” Key opinion leader
Datamonitor Healthcare’s Axial Spondyloarthritis: Marketed Drugs provides an in-depth analysis of key marketed drugs for axSpA across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>